Tuberculosis


  • Boston University Study Identifies Molecular Circuitry That Helps Tuberculosis Survive for Decades
    In a study from Boston University's National Emerging Infectious Diseases Laboratories (NEIDL), researchers have generated a map of the cellular circuitry of Mycobacterium tuberculosis, the causative agent of human tuberculosis (TB). This information, which is being ...More
    July 8, 2013 Posted in News
  • Treating TB: What Needs to be Done to Improve Treatment Rates
    People with tuberculosis (TB) in China often delay going to see a doctor for more than two weeks, finds research in BioMed Central's open access journal BMC Medicine. Reasons for this include a poor understanding of TB, increasing costs of treatment not covered by health ...More
    July 8, 2013 Posted in News
  • Scientists Discover Ethnic Differences in Immune Response to TB Bacterium
    The immune response to the bacterium that causes tuberculosis (TB) varies between patients of different ethnic origin, raising important implications for the development of tests to diagnose and monitor treatment for the disease, according to new research published today in ...More
    July 5, 2013 Posted in News
  • Researchers Find New Approach to Battling Tuberculosis
    Most humans would like to shed their fatty exteriors, but tuberculosis (TB)-causing bacteria rely on theirs for survival. Scientists at the University of Medicine and Dentistry of New Jersey (UMDNJ)-New Jersey Medical School have now discovered a drug that cripples the TB ...More
    June 18, 2013 Posted in News
  • New Compound Excels at Killing Persistent and Drug-Resistant Tuberculosis
    An international team led by scientists at The Scripps Research Institute (TSRI), the Howard Hughes Medical Institute and Albert Einstein College of Medicine of Yeshiva University has identified a highly promising new anti-tuberculosis compound that attacks the tuberculosis ...More
    June 17, 2013 Posted in News
  • WHO Issues Interim Guidance on the Use of Bedaquiline to Treat MDR-TB
    The World Health Organization (WHO) estimates that up to half a million new cases of multidrug-resistant tuberculosis (MDR-TB) occur worldwide, each year. Current treatment regimens for MDR-TB present many challenges: treatment lasts 20 months or more, requiring daily ...More
    June 17, 2013 Posted in News
  • Tracking Drug-Resistant Tuberculosis in Real Time
    Professor Frances Jamieson at the University of Toronto’s Department of Laboratory Medicine and Pathobiology (LMP), and a medical microbiologist with Public Health Ontario, is leading the way in tracking potentially deadly outbreaks of tuberculosis (TB) with a powerful new ...More
    June 13, 2013 Posted in News
  • Researchers Identify a New Mechanism of TB Drug Resistance
    Pyrazinamide (PZA) -- a frontline tuberculosis (TB) drug -- kills dormant persister bacteria and plays a critical role in shortening TB therapy. PZA is used for treating both drug susceptible and multi-drug resistant TB (MDR-TB) but resistance to PZA occurs frequently and ...More
    June 12, 2013 Posted in News
  • Experimental Vaccine Shows Promise Against TB Meningitis
    A team of Johns Hopkins researchers working with animals has developed a vaccine that prevents the virulent TB bacterium from invading the brain and causing the highly lethal condition TB meningitis, a disease that disproportionately occurs in TB-infected children and in ...More
    June 12, 2013 Posted in News
  • Targeting High-Risk Neighborhoods May Eliminate Tuberculosis
    Identifying specific neighborhoods that have a high incidence of tuberculosis followed by testing and treating the residents proved to eliminate those communities’ cases of tuberculosis, according to new research published in the American Journal of Public Health. A latent ...More
    May 22, 2013 Posted in News